HEALTHCARE GLOB. ENT. LTD
HCG · General/Diversified · NSE
₹656
Current Market Price
Under Review— We don’t have enough data to publish a fair value estimate for HCG yet. Reason: Data Limited.
Updated just now
YieldIQ Score
—
Piotroski F-Score
6/9
Economic Moat
None
Confidence
30%
ROE
1.0%
Debt/Equity
1.30
WACC
11.1%
Market Cap
₹9,793 Cr
Quality & Valuation
Neutral model outputs — no recommendations.
ROCE
14.6%
Return on capital employed
EV / EBITDA
20.2×
Enterprise multiple
Debt / EBITDA
3.5×
Leverage vs earnings
Interest Coverage
1.4×
EBIT covers interest
Current Ratio
0.81×
Short-term liquidity
Asset Turnover
0.72×
Revenue per ₹ of assets
Revenue CAGR (3Y)
14.8%
3-year revenue growth
Revenue CAGR (5Y)
19.7%
5-year revenue growth
Ratio Trends
HCG · last 9 annual periods
ROE
1.0%
ROCE
14.6%
Operating Margin
—
Debt / Equity
1.30×
PE
569.9×
EV / EBITDA
20.2×
Historical Financials
HCG · Annual, last 5 years· amounts in ₹Cr unless noted
| Metric | 2022 NSE_XBRL | 2023 NSE_XBRL | 2024 NSE_XBRL | 2025 yfinance | 2026 yfinance | CAGR |
|---|---|---|---|---|---|---|
| Revenue | ₹1383 Cr | ₹1676 Cr | ₹1890 Cr | ₹2218 Cr | ₹2538 Cr | +16.4% |
| EBITDA | ₹333 Cr | ₹303 Cr | ₹343 Cr | ₹423 Cr | ₹448 Cr | +7.7% |
| EBIT | ₹187 Cr | ₹148 Cr | ₹176 Cr | — | — | -1.5% |
| PAT | ₹53.7 Cr | ₹29.3 Cr | ₹48.2 Cr | ₹44.4 Cr | ₹13.8 Cr | -28.9% |
| EPS (diluted) | ₹3.97 | ₹2.10 | ₹3.43 | — | — | -3.6% |
| CFO | ₹220 Cr | ₹252 Cr | ₹285 Cr | ₹317 Cr | ₹347 Cr | +12.1% |
| CapEx | ₹-71.2 Cr | ₹-133 Cr | ₹-186 Cr | ₹-209 Cr | ₹-292 Cr | — |
| FCF | ₹149 Cr | ₹118 Cr | ₹98.9 Cr | ₹108 Cr | ₹55.0 Cr | -22.0% |
| Total Assets | ₹2220 Cr | ₹2316 Cr | ₹2707 Cr | ₹3543 Cr | ₹3923 Cr | +15.3% |
| Total Debt | ₹915 Cr | ₹901 Cr | ₹1274 Cr | ₹1837 Cr | ₹1735 Cr | +17.4% |
| Shareholders' Equity | ₹870 Cr | ₹861 Cr | ₹826 Cr | ₹922 Cr | ₹1332 Cr | +11.2% |
CAGR computed across the visible window. Signs reverse if start value is zero or negative.
Peer Comparison
HCG vs 5 closest peers by market-cap band
| Peer | MoS | Score | Verdict | ROE | PE |
|---|---|---|---|---|---|
JLHL JLHL | — | — | Pending | 12.6% | — |
JSLL JSLL | — | — | Pending | 47.5% | — |
PARKHOSPS PARKHOSPS | — | — | Pending | 19.2% | — |
 YATHARTH YATHARTH | — | — | Pending | 8.0% | — |
NEPHROPLUS NEPHROPLUS | — | — | Pending | 6.9% | — |
Click a ticker to view its fair-value analysis.
Dividend History
No dividend events recorded for HCG in the last 10 years.
Risk Analysis
Volatility & drawdown
Risk profile of HCG →
DuPont
ROE decomposition
Why ROE is what it is →
Technicals
RSI, MACD, MAs
Reference indicators →
News & Filings
Recent activity
BSE filings + news for HCG →
Compare
Head-to-head with peers
Compare HCG side by side →
Run Full Interactive Analysis
Interactive DCF sliders, sensitivity heatmap, peer comparison, and more.
Analyse HCGNow →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst. Past performance does not guarantee future results.